Sep 16, 20201 min readNEW EVENT! Importance of Bone Targeting Agents in Metastatic Breast CancerREGISTER NOW! This is a non-CME presentation and is not eligible for AMA PRA Category 1 CreditsTM Online Program Sponsored by Amgen, Inc. All rights reserved. USA-162X-80803
REGISTER NOW! This is a non-CME presentation and is not eligible for AMA PRA Category 1 CreditsTM Online Program Sponsored by Amgen, Inc. All rights reserved. USA-162X-80803
The First and Only Novel Targeted Therapy Approved for mCRC, Regardless of Mutation Status, in More Than a Decade1-3
コメント